Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 10/20 | 0.61 |
| ▸ | HTR3A | P46098 | 5/20 | 0.61 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.61 |
| ▸ | HTR3B | O95264 | 4/20 | 0.61 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.61 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.58 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4949371 | 0.90 | CHRNA7 (0.61) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL19996959 | 0.85 | CHRNA7 (0.61) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL19996931 | 0.82 | CHRNA7 (0.61) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL13880728 | 0.82 | HTR3A (0.63) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL13881186 | 0.82 | HTR3A (0.63) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL13881240 | 0.82 | HTR3A (0.63) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL7281353 | 0.81 | CHRNA7 (0.74) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL3499448 | 0.81 | CHRNA7 (0.74) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL3499446 | 0.81 | CHRNA7 (0.74) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL4218709 | 0.81 | CHRNA7 (0.74) | CHRNA7HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190040057-A1 | HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2019-02-07 | — | — | US | disclosed |
| US-20190040057-A1 | HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2019-02-07 | — | — | US | disclosed |
| US-9926311-B2 | Heteroaryl carboxamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-03-27 | — | — | US | disclosed |
| US-9926311-B2 | Heteroaryl carboxamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-03-27 | — | — | US | disclosed |
| US-20160214975-A1 | HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2016-07-28 | — | — | US | disclosed |
| US-20160214975-A1 | HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2016-07-28 | — | — | US | disclosed |
| US-9139579-B2 | Heteroaryl carboxamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-09-22 | — | — | US | disclosed |
| US-9139579-B2 | Heteroaryl carboxamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-09-22 | — | — | US | disclosed |
| US-20130144062-A1 | HETEROARYL CARBOXAMIDES | Bayer Pharma AG (DE) | 2013-06-06 | — | — | US | disclosed |
| US-20130144062-A1 | HETEROARYL CARBOXAMIDES | Bayer Pharma AG (DE) | 2013-06-06 | — | — | US | disclosed |
| US-20080009624-A1 | Heteroaryl carboxamides | BAYER HEALTHCARE AG (DE) | 2008-01-10 | — | — | US | disclosed |
| US-20080009624-A1 | Heteroaryl carboxamides | BAYER HEALTHCARE AG (DE) | 2008-01-10 | — | — | US | disclosed |
| US-20080009624-A1 | Heteroaryl carboxamides | BAYER HEALTHCARE AG (DE) | 2008-01-10 | — | — | US | disclosed |
| EP-1448530-B1 | HETEROARYL CARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2007-10-03 | — | — | EP | disclosed |
| US-7256288-B2 | Heteroaryl carboxylic acid amides | BAYER HEALTHCARE AG (DE) | 2007-08-14 | — | — | US | disclosed |
| US-7256288-B2 | Heteroaryl carboxylic acid amides | BAYER HEALTHCARE AG (DE) | 2007-08-14 | — | — | US | disclosed |
| US-7256288-B2 | Heteroaryl carboxylic acid amides | BAYER HEALTHCARE AG (DE) | 2007-08-14 | — | — | US | disclosed |
| US-20050209236-A1 | Heteroaryl carboxylic acid amides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2005-09-22 | — | — | US | disclosed |
| EP-1448530-A1 | HETEROARYL CARBOXYLIC ACID AMIDES | Bayer HealthCare AG (DE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003043991-A1 | HETEROARYL CARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130144062-A1 | HETEROARYL CARBOXAMIDES | GRIN2A, GRIN2C, CNR2 | CHRNA7 41/4885HTR3A 318/4885HTR3E 322/4885 |
| US-20160214975-A1 | HETEROARYL CARBOXAMIDES | GRIN2A, GRIN2C, CNR2 | CHRNA7 41/4885HTR3A 318/4885HTR3E 322/4885 |
| US-20190040057-A1 | HETEROARYL CARBOXAMIDES | CNR2, GRIN2A, CNR1 | CHRNA7 52/4885HTR3A 194/4885HTR3E 252/4885 |
| US-20050209236-A1 | Heteroaryl carboxylic acid amides | HCAR2, HCAR1, HCAR3 | CHRNA7 153/4885HTR3A 536/4885HTR3E 1131/4885 |
| US-20080009624-A1 | Heteroaryl carboxamides | GRIN2A, GRIN2C, CNR2 | CHRNA7 41/4885HTR3A 318/4885HTR3E 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.